Harvard Partners Warfarin Dose-Finding Study Incorporates Genetic Data, Pharmacoeconomics

At a time when the FDA is on the brink of changing warfarin’s label to reflect genetic information, the study aims to measure patient outcomes and cost when such information is used to make clinical decisions about warfarin.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.